FY2024 Earnings Forecast for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.41) for the year, down from their prior estimate of ($0.39). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q3 2025 earnings at ($0.10) EPS.

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Price Performance

Shares of Oncolytics Biotech stock opened at C$1.48 on Monday. The stock has a market capitalization of C$113.75 million, a price-to-earnings ratio of -3.68 and a beta of 1.35. The firm’s 50-day moving average price is C$1.50 and its two-hundred day moving average price is C$1.45. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. Oncolytics Biotech has a 1-year low of C$1.15 and a 1-year high of C$2.32.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.